Handelsavisen
prelaunch
Companies Healthcare 7707.T
77
7707.T Tokyo Stock Exchange Advanced Medical Equipment & Technology

Precision System Science Co Ltd

¥193,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
8,3 %
ROE
1,5 %
Net margin
7,5 %
Debt / equity
0,31
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Precision System Science Co Ltd designs and develops advanced medical equipment and technology, primarily serving the healthcare sector through specialized diagnostic and therapeutic solutions.

Business. Precision System Science Co Ltd (7707.T) is a Japanese company engaged in the Advanced Medical Equipment & Technology industry within the Healthcare Services & Equipment sector. The firm primarily operates through a product-sale revenue model, focusing on the development and distribution of medical devices and related technologies. Headquartered in Japan, the company is listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
1,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 7707.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 7707.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Precision System Science Co Ltd (7707.T) is a Japanese company engaged in the Advanced Medical Equipment & Technology industry within the Healthcare Services & Equipment sector. The firm primarily operates through a product-sale revenue model, focusing on the development and distribution of medical devices and related technologies. Headquartered in Japan, the company is listed on the Tokyo Stock Exchange. Specific details regarding operating segments and geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Precision System Science Co Ltd maintains a strong liquidity position, with cash and equivalents amounting to ¥20,496,960,000, which significantly exceeds its total liabilities of ¥2,177,686,000. The company's debt-to-equity ratio of 0.31 indicates a conservative capital structure, and its current ratio of 2.66 suggests a solid ability to meet short-term obligations.

    The company's profitability metrics, including a return on equity of 1.52% and a return on assets of 1.03%, are below the typical thresholds for high-growth or high-margin industries. These figures suggest that the company is generating modest returns relative to its equity and asset base.

    Precision System Science Co Ltd operates in a single business segment focused on advanced medical equipment and technology. Its geographic exposure is not disclosed in the available data, but the company's revenue concentration in one segment implies that its performance is closely tied to the healthcare equipment market.

    The company's growth trajectory is not explicitly outlined in the available data, but its current financial performance suggests a stable, rather than rapidly growing, business. The absence of significant revenue or earnings growth in the most recent period indicates a need for further analysis of its long-term growth potential.

    The risk assessment for Precision System Science Co Ltd indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative capital structure and strong cash reserves reduce the likelihood of near-term financial distress.

    Recent financial filings and transcripts do not provide specific details on the company's strategic initiatives or operational changes. However, the absence of significant dilution or liquidity risks suggests that the company is maintaining a stable financial position.

    Key takeaways
    • Precision System Science Co Ltd maintains a conservative capital structure with a low debt-to-equity ratio and strong liquidity.
    • The company's profitability metrics are modest, indicating a need for improvement in returns on equity and assets.
    • The company operates in a single business segment focused on advanced medical equipment and technology.
    • There are no immediate liquidity or dilution risks, suggesting a stable financial position.
    • The company's growth trajectory is not clearly defined in the available data, indicating a need for further analysis.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 2

    Free cash flow improved by 90.8% year-over-year, reaching a loss of only 68 million yen.

    Long-term debt decreased to 564 million yen in FY2025, down from 1.37 billion yen in FY2024.

    BEAR CASE · 4

    The company reported a net loss of 253 million yen in FY2025, continuing a trend of negative earnings.

    Free cash flow remained negative at 68 million yen in FY2025, indicating ongoing cash burn.

    Gross profit fell to 1.38 billion yen in FY2025, down from 3.1 billion yen in FY2021.

    Return on assets of 1.0% suggests inefficient utilization of the company's asset base.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-16
    Q4 2025 · Quarter highlights

    Revenue ¥1.22B, +8,9% YoY; Operating income +142,3% YoY.

    Revenue¥1.22B+8,9 % YoY
    Operating income¥27.6M+142,3 % YoY
    Net income¥7.5M+109,8 % YoY
    Free cash flow
    EPS
    Operating cash flow-¥284.8M−386,8 % YoY
    Financials
    Income statement
    Revenue¥1.22B
    Gross profit¥377.5M
    Operating income¥27.6M
    Net income¥7.5M
    Margins
    Gross margin31.0%
    Operating margin2.3%
    Net margin0.6%
    FCF margin
    Balance sheet
    Total assets¥5.28B
    Total liabilities¥1.43B
    Total equity¥3.85B
    Cash & equivalents¥1.01B
    Long-term debt¥836.7M
    Cash flow
    Operating cash flow-¥284.8M
    CapEx-¥38.2M
    Free cash flow
    SBC
    P&L flow · revenue → net income
    Revenue ¥1.22BOperating costs ¥1.19BTax ¥20.0MNet income ¥7.5M
    Highlights
    • Revenue ¥1.22B, +8,9% YoY
    • Operating income +142,3% YoY
    • Net income +109,8% YoY
    • Net margin 0.6%

    Valuation TTM

    Market price
    ¥193,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥4.58B
    Net cash
    ¥613.1M
    Current ratio
    2.7
    Debt / equity
    0.3
    ROA
    1.0%
    ROE
    1.5%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin8,3 %Above median
    Net Margin7,5 %Above median
    ROE1,5 %Above median
    D/E0,31Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Return On Assets
      net_income / total_assets
    Source documents
    • Precision System Science Co Ltd Market data — financials · 2026-05-27
    • Precision System Science Co Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    7707.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-02-16 12:30 UTCEARNINGSQuarterly results — Q4 2025 Revenue JPY 1.22B · Net JPY 7.5M
    2025-11-14 09:20 UTCEARNINGSQuarterly results — Q3 2025 Revenue JPY 1.32B · Net JPY 54.4M
    2025-08-14 09:31 UTCEARNINGSQuarterly results — Q2 2025 Revenue JPY 1.23B · Net JPY -66.9M
    2025-08-14 09:31 UTCEARNINGSAnnual results — FY 2025 Revenue JPY 4.69B · Net JPY -253.1M
    2025-05-15 12:30 UTCEARNINGSQuarterly results — Q1 2025 Revenue JPY 1.26B · Net JPY -30.1M
    2025-02-14 12:30 UTCEARNINGSQuarterly results — Q4 2024 Revenue JPY 1.12B · Net JPY -76.6M
    2024-11-14 12:30 UTCEARNINGSQuarterly results — Q3 2024 Revenue JPY 1.08B · Net JPY -79.5M
    2024-08-14 12:30 UTCEARNINGSQuarterly results — Q2 2024 Revenue JPY 1.04B · Net JPY -463.6M
    2024-08-14 12:30 UTCEARNINGSAnnual results — FY 2024 Revenue JPY 3.98B · Net JPY -1.12B
    2024-05-15 12:30 UTCEARNINGSQuarterly results — Q1 2024 Revenue JPY 929.1M · Net JPY 69.8M
    2023-08-14 12:30 UTCEARNINGSAnnual results — FY 2023 Revenue JPY 5.28B · Net JPY -1.32B
    2022-08-12 12:30 UTCEARNINGSAnnual results — FY 2022 Revenue JPY 7.43B · Net JPY 45.3M
    2021-08-13 11:45 UTCEARNINGSAnnual results — FY 2021 Revenue JPY 9.30B · Net JPY 796.0M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage